Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
about
Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteersUpdate on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentFocus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infectionsActivity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium aviumEfficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistanceIn vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosisRandomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patientsGender analysis of moxifloxacin clinical trialsMultiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex DialyzersEfficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study.A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaePharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens.Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosisMoxifloxacin dosing in post-bariatric surgery patients.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.Activity of and resistance to moxifloxacin in Staphylococcus aureus.Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects.Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytesPharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunctionAssessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy womenMoxifloxacin in the treatment of skin and skin structure infections.Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study.
P2860
Q24607103-496F3D80-835E-4980-A927-31EBFCBA7CDAQ24646866-7688E314-37F4-42BB-8AA4-8D9546C3634DQ26746197-724CA8EC-4D08-4765-BA19-A9AF967193CFQ28345248-6BCE9C51-415E-4AD7-82FD-9385F174D3CAQ28361569-D4962BFE-1E5F-4F22-BC33-75A89D54C252Q28368317-D0E62DD6-6037-4DF8-BF16-51F762D5F230Q28369466-BA05C395-7748-4872-B949-5A18C34BF667Q28534495-48F9E0A6-1D50-42C7-A431-37B19C05EBBFQ28538319-9B9F1047-00FA-470A-B4C5-860F5365FA95Q33559026-DB468257-A841-4601-AB0F-310107B53222Q33559055-179C5FC6-36F0-40D5-8257-A01FAEFB4A7CQ33681401-DDA4AFC7-177C-4EC1-AC8E-D0169BD488A6Q33812856-C76CFCE3-672B-41BE-A7E6-5F5D525AD1F6Q33874674-12D85EB5-B4C5-4ECC-98F3-AE989D8C0D1BQ33935424-3E58BC8F-E2F6-4B50-BA2B-63490DB4BAF0Q33978146-D647B938-CBC8-4B04-9BB5-F029E3C74DF4Q33980661-5E95F749-30E7-448C-B09A-AF7CAFD98665Q33983643-13797946-99C4-4810-9FE6-EEA95065D455Q34057534-E562B2DF-92E8-485E-A5EB-591B83E25071Q34098582-E88EA6DD-223E-428F-998B-4F0E4276B316Q34108091-4961EF1E-5983-4AED-91F1-D00948AC26D6Q34209532-F78B0BAB-C851-447F-9C37-657797381120Q34509728-69F04933-6222-47E8-9A6F-0451881965DDQ34882995-9AAC46FE-268D-4F7D-A3DF-4401CB6F8094Q34885313-962F970F-236A-4C5E-A231-DBB12FEC7969Q35142403-37F4460A-89D2-4851-932C-96D402E1044AQ35169086-C47B53E4-DBC8-4B54-806B-C4D2D5FB76EFQ35169089-E337E595-0376-4A1C-99EA-1A58A85850C3Q35191364-2584C396-AF15-4373-8AF7-64D675078544Q35545104-EF85037B-B9D8-4A42-8993-D8051148E6C7Q35666457-D77ED95E-65BF-4E43-B8B5-72608F70CAB6Q35708176-69E21566-95C9-41FC-91FF-C2A2FA1374A4Q35803737-0BDF400E-9D89-45B9-B9BF-0F94FD8E6A70Q35827140-4D0D5ADA-DD67-4C04-9F36-947665B4B0F6Q35919259-0A4FEDEB-AE68-416E-AD3F-641A941D185BQ35960685-A7ABAA13-50AD-41CE-8592-3F7E4D874D1DQ36054313-C81B6F28-E7D6-4F2E-8379-8EDC09D62894Q36313268-56931F3A-9206-4394-8CBD-E7A00AA4F130Q36593657-B237C662-A56A-4FB0-AE59-08F428D52AB5Q36688587-66F76A9F-202D-4F47-A07D-15E64BD04BDA
P2860
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Pharmacokinetics, safety, and ...... ministered to healthy subjects
@en
Pharmacokinetics, safety, and ...... inistered to healthy subjects.
@nl
type
label
Pharmacokinetics, safety, and ...... ministered to healthy subjects
@en
Pharmacokinetics, safety, and ...... inistered to healthy subjects.
@nl
prefLabel
Pharmacokinetics, safety, and ...... ministered to healthy subjects
@en
Pharmacokinetics, safety, and ...... inistered to healthy subjects.
@nl
P2093
P2860
P1476
Pharmacokinetics, safety, and ...... ministered to healthy subjects
@en
P2093
P2860
P304
P407
P577
1998-08-01T00:00:00Z